· Tempus AI, Inc. (NASDAQ: TEM) started 2025 announcing the National Launch of its FDA -approved xT CDx Test, a 648-gene next-generation sequencing test for solid tumor profiling, which includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback